The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The new project will be the second stage of the QSkin study, which has documented the disease in 44,000 Australians and developed a melanoma risk predictor.
Analyzing mutational signatures in cancer cell lines and xenografts, investigators identified mutagenic processes that do or don't remain active in vitro.
Researchers documented genetic associations, trait heritability, and more with data from GWAS on 778 binary or non-binary traits in UK Biobank participants.
The transcriptomes of recessive dystrophic epidermolysis bullosa squamous cell carcinoma also suggested a role for inflammation in disease development.
